|Benefits||Value for the customer|
|Science driven||Incorporates latest research insights to allow clients to use their time more efficiently and focus on their core research activities.|
|Customized solutions||Allow seamless integration with clients ongoing research and caters to their specific preclinical and clinical research needs.|
|Quicker Turn Around Time at an affordable cost||Robust and validated pipelines enable clients to complete their research in a shorter timeframe while minimizing the overall cost.|
|Partnership||Supports clients need in creating presentation materials, figures for manuscripts and summary reports.|
|Accelerate your immuno-oncology research using OncoPeptTM|
Provides immune phenotyping of the tumor microenvironment and analyses potenial biomarkers of response to enable success of checkpoint inhibitors.
Tumor microenvironment analysis
|Tissue type requirement||
|Effort, time and cost||
Delivers prioritized T-cell neo-epitopes, that can be used as DNA vaccine or peptide vaccine for cancer immunotherapy
OncoPeptVACTM uses multiple filters to eliminate greater than 99% of neo-antigens to select true T-cell neo-epitopes
Tumor neo-epitope analysis
Delivers prioritized T-cell neo-epitopes, that can be used as DNA or peptide vaccine for cancer immunotherapy
The database captures CD4+/CD8+ T-cell neo-epitopes from neo-antigens based on their binding affinity to different HLA types and selected based on their expression in cancer cells. Mutated genes are rank ordered according to their T-cell neo-epitope burden.
The analysis provides an explanation as to why T-cell neo-epitopes are largely private and not shared between samples.
OncoPeptTOPETM web interface allows visualization of neo-epitopes across genes and cancers. Data is accessed by Gene/Transcript ID and/or variant information. Data can be filtered further on HLA type and prevalence of the mutant epitope across different cancers